Over the past three years, thousands and thousands of US families - many of whom first discovered Kendamil during the 2022 infant formula crisis - have trusted us with something incredibly precious: feeding their babies. We’re deeply grateful for that trust.
When we entered the U.S. as the first international responder to the crisis, we did so under Enforcement Discretion in partnership with the White House and the FDA - a temporary pathway created to bring safe, high-quality formulas into the country during a time of urgent need. Since then, a tremendous amount of work has been happening behind the scenes with one simple goal: making sure Kendamil can remain a long-term choice for families in the United States for generations to come.
As part of that process, we completed clinical growth studies and went through a comprehensive review covering nutrition, manufacturing, quality testing, labeling, and ongoing monitoring, in partnership with FDA. This work ensures Kendamil meets all U.S. infant formula requirements, while continuing to be made in Europe using the same nutritional principles, ingredients, and care we’ve followed for more than 60 years.